Dolly Khanna has returned to Dalal Street and is scouting for potential multibagger stocks to tuck into. Her latest stock pick has the credentials to delight investors, according to a noted expert
Subscribe to Blog via Email
Join 495 other subscribers
- DCX Systems has the ability to become a key player in EMS space. TP ₹466 (+54%)DCX Systems has the ability to become a key player in EMS space with huge potential in railway & defence. It has ability to deliver high value complicated & critical products for leading defense players L&T & Lockheed. Order book ₹3000 Cr. TP ₹466 (+54%) Download... DCX Systems has the ability to become a key […]
- Affle has a unique business model, unmatched network effects & prudent acquisition strategyAffle has a unique business model, unmatched network effects & prudent acquisition strategy. It is well-positioned to capitalize on growth in digital advertising in high-potential sectors such as e-commerce, fintech, gaming & entertainment. TP ₹2538 (60%) Download research report ... Affle has a unique business model, unmatched network effects & prudent acquisition strategy
- Concord Biotech is a good buy after 30% correction. Jhunjhunwala holds stock in portfolioConcord Biotech is one of the stocks in the portfolio of Rakesh Jhunjhunwala. Rekha Rakesh Jhunjhunwala holds 25,199,240 equity shares, or 24.09 per cent stake in the company as of September 30, 2024. Her stake in the company as of November 14, 2024 is worth Rs 4,675 crore. Concord Biotech has a market capitalization of […]
Recent Posts
- NTPC Green Energy Ltd has exponential growth potential. Subscribe to the IPO: SBI Securiies
- DCX Systems has the ability to become a key player in EMS space with huge potential lying ahead in the railway and defence space. Buy for target price of ₹466 (54% upside): KR Choksey
- Affle (India) has strong revenue growth with margin expansion. Buy for target price of ₹2538 (60.3%): Keynote Capitals
- Ratnaveer Precision Engineering has strong demand traction, capacity expansions and favourable product mix. Buy for target price of ₹290 (36% upside): ICICI Direct
- Repco Home Finance is the beneficiary of tailwinds in the housing sector. Buy for target price of ₹610 (32% upside): Nuvama
Recent Comments